Medical castration in the treatment of widespread cancers of the prostate. The role of buserelin

Medical castration in the treatment of widespread cancers of the prostate. The role of buserelin

Blog Article

Medical castration with LHRH agonists is a significant trend in the treatment of face toner locally advanced and metastatic prostate cancer (PC).The article is devoted to the effectiveness of synthetic LHRH agonist buserelin (Buserelin-depo) in the treatment of patients with hormone dependent PC.Administration of Buserelin-depot results in a decrease Power Entry Module of the prostate-specific antigen levels, stable reduction of serum testosterone to postcastration level, reduction in the size of the prostate and fewer voiding dysfunction symptoms without any serious side effects.